I lost about the same % and sold all after P3 fiasco. Moved remaining money to GILD, AMGN, BMY and RNN. Made what I lost with ONCY back in 2 months and now ahead - my advice do the same. ONCY has no P3 in the works and none planned. Other players include AMGN with oncolytic herpes, VRACY with coxsackie oncolytic with very promising P2 data similar to AMGN results is more certain than ONCY at this point.
Glad someone is helping to design the trials (finally!) but a P3 success is still required no matter how may ODDs, how many years away is that?? - better investments are BMY, AMGN, GILD and for speculation RNN. Also check out VRACY - P2 data pending.
ONCY is one company among many with an oncolytic virus. The unmodified REOvirus is lagging behind at least 2 competitors - AMGN and VRACY - "head and shoulders" is a misrepresentation. ONCY potential for acquisition has been answered by the PPS. Unless management can have a successful P3 this company is not advancing - the current P1 and P2 and ODD suggest a treatment in search of a disease and an attempt for a short bump to dump more shares. Better investments IMO are GILD, AMGN, BMY and for speculation RNN.
Oncy needs to design a P3 and quick - if they can. Most non-modified viruses apparently do not have the ability to be as efficacious as needed which is why modified oncolytics will be the goto treatment options. Modified viruses from herpes, vaccinia, paramyxo and adenovirus are ready and are being tested to see which cancer and combo works. MAybe Reo will have some niche treatment that it works best at but the stock price kind of reflects that chance (should be lower). Beginning more P1 trials to find the right cancer for Reo - if possible - is also a negative - again a treatment in search of a disease. ODD still requires proof of activity hence the P3 requirement. Better trades are AMGN, BMY, GILD and for speculation RNN.
This company has nothing in a P3 trial except for failures. Many P2's but no real randomized data just lots of promise ( 15 years of promise), ODD is just more smoke to try and delay/prevent the coming delisting. Steer clear of this company IMO; better buys are BMY, AMGN (Oncolytic virus that works in P3) GILD and for speculation RNN.